WO1996004032A1 - Embout interchangeable pour inhalateurs a tablette de substance active integree, consolidee, annulaire - Google Patents
Embout interchangeable pour inhalateurs a tablette de substance active integree, consolidee, annulaire Download PDFInfo
- Publication number
- WO1996004032A1 WO1996004032A1 PCT/EP1995/002750 EP9502750W WO9604032A1 WO 1996004032 A1 WO1996004032 A1 WO 1996004032A1 EP 9502750 W EP9502750 W EP 9502750W WO 9604032 A1 WO9604032 A1 WO 9604032A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet
- mouthpiece
- tablet holder
- interchangeable
- ring
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title abstract description 6
- 239000002245 particle Substances 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims description 13
- 239000011324 bead Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 abstract description 2
- 238000002664 inhalation therapy Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000003754 machining Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002644 respiratory therapy Methods 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Dexbudesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 102000008736 Snapin Human genes 0.000 description 1
- 108050000529 Snapin Proteins 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
- A61M2202/066—Powder made from a compacted product by abrading
Definitions
- the invention relates to an interchangeable mouthpiece for inhalers for the mechanical production of dosed inhalable active ingredient particles with an integrated, solidified, ring-shaped active ingredient tablet and an inhalation tube which can be axially displaced in the mouthpiece, at the end of which is directed towards the dosing agent, the tablet is fastened in a tablet holder .
- the object of the invention is to improve and simplify the interchangeability of the mouthpiece and at the same time the axial and radial stability of the mouthpiece with respect to the inhaler drive unit, i.e. especially to optimize their dosing agents.
- a tablet holder guide is proposed for this purpose, which connects the mouthpiece to the inhaler drive unit.
- This tablet holder guide creates an integral unit between the mouthpiece and the inhaler drive unit.
- the tablet holder guide stabilizes the position of the tablet in relation to the dosing agent in a very precise way. This makes it possible to generate the required doses of the active ingredient tablet very precisely and reproducibly.
- the invention makes the handling of the inhaler by the user more consumer-friendly.
- the tablet holder guide according to the invention enables the mouthpiece to be replaced by movements which are also common in everyday life, in particular in older people - lifting off a closure cap by tilting the spray can, rotating the tank cap. Despite these simple movements, the tablet according to the invention stabilizes the connection between the mouthpiece and the inhaler drive unit is surprisingly very precise.
- the tablet holder guide has an annular bead at the end directed towards the mouthpiece which engages in an annular recess in the mouthpiece.
- the dimensions of the bead and the ring groove are chosen so that due to a certain flexibility of the tablet holder guide and mouthpiece, both a snap-in and a take-out are possible. Tilting the mouthpiece is enough to take it out, an inclined insertion and pressing is enough to insert it.
- This compound is referred to herein as a -Sia ⁇ M- compound.
- the axial guidance of the tablet holder has, according to the invention, at least one rotating lug on the circumference, which is arranged to be axially movable in a slot in the tablet holder guide.
- the axial guidance is not limited to the area of the munster / inhalation tube alone, as in the prior art. This area becomes smaller as the tablet is removed.
- the guidance of the tablet holder in the slots of the tablet holder guide is always uniformly and precisely independent of the degree of removal of the tablet.
- the tablet holder guide has, according to the invention, a locking bead which interacts with locking pins on the inhaler drive unit.
- the locking bead has at least two recesses distributed symmetrically on the circumference, which cooperate with the locking pins in a bayonet-like manner. That is, by inserting the pins into the recess and making a small rotation, the mouthpiece and the inhaler drive unit are connected to one another or detached from one another.
- a cover cap is provided to cover the locking mechanisms and can be fastened to the locking pin via a further snap-in connection.
- the tablet holder has molded parts protruding on the surface directed against the tablet, which correspond to correspondingly shaped depressions in the tablet surface. This improves the integration of the tablet in the tablet holder.
- This configuration of the tablet and tablet holder according to the invention makes it possible, compared to the prior art, to do without the tablet being fixed in the tablet holder by gluing. Adhesives are fundamentally disadvantageous for medication and require elaborate approvals.
- clamping elements can be assigned to the molded parts.
- the invention proposes to design it in two parts, the inhalation tube being attachable to the tablet holder.
- the solidified, ring-shaped active ingredient tablets can be produced by means of various known techniques, the number of individual dosages in the range of 50-300 or more can be predetermined via the length dimension of the ring tablet.
- active ingredients which can be micronized and which have to be dosed at a low level can be used. This also applies in particular to the active ingredients that cannot be suspended in CFCs or that are denatured by CFCs. All active ingredients that are absorbed by inhalation in the lungs can be used. These are in particular:
- Respiratory therapy e.g.
- budesonide from the group of steroids: budesonide, R-budesonide, beclometasone, fluticasone and others;
- - peptide hormones insulin, calcitonin, desmopressin and others;
- - chemotherapy drugs e.g. Pentamidine and others
- the mouthpiece unit is advantageously housed in an airtight container with desiccant. After replacing the used unit or tablet, the container can be used as a new closure cap for the inhaler.
- the container is designed in such a way that a special holder provides the prerequisite for also accommodating individual active ingredient ring tablets.
- FIG. 1 shows the core of the subject matter of the invention inhalation tube / tablet holder / ring tablet
- Fig. 2 shows the mouthpiece unit
- FIG 3 shows the complete inhaler consisting of inhaler drive unit and mouthpiece unit.
- Fig. 1 denotes the ring tablet, which is located in the tablet holder 2.
- 2 molded parts 5 are arranged on the tablet holder for fastening them. These can consist of simple pins of different cross-sections, for example cones, the O 96/04032 -, ⁇ -, -., ⁇ -.
- Corresponding depressions are assigned to the molded parts 5 in the ring tablet 2.
- clamping elements 6, for example Feder ⁇ elements are all or only some mold parts 5 clamping elements 6, for example Feder ⁇ elements, assigned to the ring tablet 4 to be fixed in the axial direction and secure it against falling out.
- the inhalation tube 1 is attached to the tablet holder 2 in the form of a cone connection.
- a one-piece design tablet holder / inhalation tube - as shown in FIG. 2 - is also encompassed by the invention.
- Two opposite guide lugs 3 are formed on the tablet holder 2 and are used to secure the tablet holder 2 against rotation.
- the guide lugs 3 also serve in the axial direction as a stop to limit the tablets when they reach the locking bead 11.
- the inhalation tube 1 located on the tablet holder 2 is guided precisely on its outer diameter in the inhaler mouthpiece 7.
- a compression spring 8 which fits onto the inhalation tube 1 ensures that the end face of the ring tablet 4 is pressed onto the metering means 16 of the inhaler with a predeterminable spring force.
- a dosing agent elements are used which cause abrasion from the ring tablet by rotation and thus generate a dose of active ingredient.
- Such a dosing agent is known in the form of an end mill from WO 93 / - ⁇ - £ l.
- the tablet holder 2 is additionally guided precisely in the tablet holder guide 9, namely through the guide lugs 3. These are located in slot-shaped recesses which run vertically in the tablet holder guide 9. The tablet holder is also secured against twisting.
- the tablet holder guide 9 is rigidly attached on its other side to the mouthpiece 7 with a snap-in connection 19 and secured by a stiff coupling ring 10.
- the mouthpiece unit is constantly pressed in the axial direction onto the abutment surfaces 15 of the inhaler drive unit 18 by means of a cover cap 13 which engages with the inhaler guide pins 14 in a snap-in connection.
- the cover cap 13 can be easily removed by hand, so that the exchange of a used active ingredient ring tablet 4 or the entire mouthpiece unit is possible at any time.
- All parts can be made of plastic using injection molding technology or using conventional machining methods.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
Embout interchangeable pour inhalateurs de poche, à tablette de substance active intégrée, très rigide, annulaire, à la partie avant desquels des particules de grosseur inhalable sont générées de façon dosée, de telle manière que même des substances hautement actives nécessitant un faible dosage et qui sont résorbées dans les poumons peuvent être administrées par inhalation pour des usages thérapeutiques.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU31105/95A AU3110595A (en) | 1994-08-04 | 1995-07-13 | Exchangeable mouthpiece for inhalers with integrated, consolidated, ring-shaped active substance tablet |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4427527.7 | 1994-08-04 | ||
DE4427527 | 1994-08-04 | ||
DEP4429707.6 | 1994-08-22 | ||
DE4429707A DE4429707C1 (de) | 1994-08-04 | 1994-08-22 | Inhalator mit integrierter, verfestigter, ringförmiger Wirkstofftablette |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996004032A1 true WO1996004032A1 (fr) | 1996-02-15 |
Family
ID=25938934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/002750 WO1996004032A1 (fr) | 1994-08-04 | 1995-07-13 | Embout interchangeable pour inhalateurs a tablette de substance active integree, consolidee, annulaire |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3110595A (fr) |
WO (1) | WO1996004032A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10326830B3 (de) * | 2003-06-12 | 2004-06-24 | Msa Auer Gmbh | Steckverbindung für Atemanschlüsse |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993024165A1 (fr) * | 1992-05-29 | 1993-12-09 | Ggu Gesellschaft Für Gesundheits- Und Umweltforschung Mbh & Co. Vertriebs Kg | Dispositif generateur de particules inhalables de substances actives |
-
1995
- 1995-07-13 AU AU31105/95A patent/AU3110595A/en not_active Abandoned
- 1995-07-13 WO PCT/EP1995/002750 patent/WO1996004032A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993024165A1 (fr) * | 1992-05-29 | 1993-12-09 | Ggu Gesellschaft Für Gesundheits- Und Umweltforschung Mbh & Co. Vertriebs Kg | Dispositif generateur de particules inhalables de substances actives |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10326830B3 (de) * | 2003-06-12 | 2004-06-24 | Msa Auer Gmbh | Steckverbindung für Atemanschlüsse |
Also Published As
Publication number | Publication date |
---|---|
AU3110595A (en) | 1996-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0642366B1 (fr) | Dispositif generateur de particules inhalables de substances actives | |
EP0545960B1 (fr) | Inhalateur sans gaz propulseur | |
DE69633645T2 (de) | Vorrichtung zum Verabreichen von Medikamenten | |
DE60017886T2 (de) | Pulverinhalator für ein kombiniertes medikament | |
DE69129188T2 (de) | Inhalator mit einem reservoir für mehrere dosierte inhalationsmittel, mit transportvorrichtung und mit wirbelkammer | |
DE69108929T2 (de) | Aerosol-abgabevorrichtung mit anzeigeanordnung. | |
EP0611577B1 (fr) | Inhalateur de poudres | |
DE69128151T2 (de) | Inhalationsvorrichtung | |
DE69617431T2 (de) | Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator | |
DE69503499T2 (de) | Pulverinhalator | |
DE69529104T2 (de) | Inhalator | |
DE69000249T2 (de) | Zur vollstaendigen entleerung der kapsel geeigneter inhalator. | |
DE69617754T2 (de) | Inhalator | |
DE69210607T2 (de) | Inhalator für Medikamente in Pulverform | |
DE2642174A1 (de) | Vorrichtung zum abgeben eines aerosols | |
EP1474195B1 (fr) | Appareil auxiliaire d'inhalation | |
DE2625925A1 (de) | Inhaliervorrichtung | |
EP0547429A1 (fr) | Inhalateur de poudres | |
DE2106794A1 (de) | Vorrichtung zum Apphzieren einer abgemessenen Pulvermenge unter Druck | |
EP1220700A1 (fr) | Inhalateur de respiration controlée pour poudre | |
DE69632192T2 (de) | Elektrostatisches versprühen | |
CH629102A5 (de) | Inhalationsgeraet. | |
EP0373237A1 (fr) | Dispositif d'inhalateur de poche | |
WO2000022570A1 (fr) | Dispositif compteur | |
DE3224562A1 (de) | Dosierungsinhalator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BB BG BR CA CN CZ FI GE HU JP KG KP KZ LK LT LV MD NO NZ PL RO RU SI SK TJ TT UA US UZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995926873 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995926873 Country of ref document: EP |
|
122 | Ep: pct application non-entry in european phase |